

Genomes for Kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing

Scott Newman [1,4], Joy Nakitandwe [2,4], Chimene A. Kesserwan [3,4], Elizabeth M. Azzato [2,4], David A. Wheeler [1,4], Michael Rusch [1], Sheila Shurtleff [2], Dale J. Hedges [1], Kayla V. Hamilton [3], Scott G. Foy [1], Michael N. Edmonson [1], Andrew Thrasher [1], Armita Bahrami [2], Brent A. Orr [2], Jeffery M. Klco [2], Jiali Gu [2], Lynn W. Harrison [3], Lu Wang [2], Michael R. Clay [2], Anastasia Ouma [3], Antonina Silkov [1], Yanling Liu [1], Zhaojie Zhang [1], Yu Liu [1], Samuel W. Brady [1], Xin Zhou [1], Ti-Cheng Chang [1], Manjusha Pande [1], Eric Davis [1], Jared Becksfort [1], Aman Patel [1], Mark R. Wilkinson [1], Delaram Rahbarinia [1], Manish Kubal [3], Jamie L. Maciaszek [2], Victor Pastor [1], Jay Knight [1], Alexander M. Gout [1], Jian Wang [1], Zhaohui Gu [2], Charles G. Mullighan [2], Rose B. McGee [3], Emily A. Quinn [3], Regina Nuccio [3], Roya Mostafavi [3], Elsie L. Gerhardt [3], Leslie M. Taylor [3], Jessica M. Valdez [3], Stacy J. Hines-Dowell [3], Alberto S. Pappo [3], Giles Robinson [3], Liza-Marie Johnson [3], Ching-Hon Pui [3], David W. Ellison [2,4], James R. Downing [2,4], Jinghui Zhang [1,4], Kim E. Nichols [3,4]

1. Department of Computational Biology, St Jude Children's Research Hospital
2. Department of Pathology, St Jude Children's Research Hospital
3. Department of Oncology, St Jude Children's Research Hospital
4. Contributed Equally

RUNNING TITLE: Comprehensive clinical sequencing in pediatric cancer

KEY WORDS: Cancer, genomics, pediatric, DNA, RNA, next generation sequencing

ADDRESS CORRESPONDENCE TO:

Kim E. Nichols, MD

Department of Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Place

Memphis, TN 38105

901-595-8385 (office)

901-595-6086 (fax)

kim.nichols@stjude.org

Jinghui Zhang, PhD

Department of Computational Biology

St. Jude Children's Research Hospital

262 Danny Thomas Place

Memphis, TN 38105

901-595-6829 (office)

901-595-7100 (fax)

jinghui.zhang@stjude.org

CONFLICTS OF INTEREST:

The authors have no conflicts of interest to disclose.

WORD COUNT: 8881

NUMBER OF FIGURES: 7

NUMBER OF SUPPLEMENTAL FIGURES: 6

NUMBER OF SUPPLEMENTAL TABLES: 17

ABSTRACT

Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-risk disease. Here, we used a three-platform sequencing approach, including whole genome (WGS), exome, and RNA sequencing, to examine tumor and germline genomes from 309 prospectively identified children with newly diagnosed (85%) or relapsed/refractory (15%) cancers, unselected for tumor type. Eighty-six percent of patients harbored diagnostic (53%), prognostic (57%), therapeutically-relevant (25%), and/or cancer predisposing (18%) variants. Inclusion of WGS enabled detection of activating gene fusions and enhancer hijacks (36% and 8% of tumors, respectively), small intragenic deletions (15% of tumors) and mutational signatures revealing of pathogenic variant effects. Evaluation of paired tumor-normal data revealed relevance to tumor development for 55% of pathogenic germline variants. This study demonstrates the power of a three-platform approach that incorporates WGS to interrogate and interpret the full range of genomic variants across newly diagnosed as well as relapsed/refractory pediatric cancers.

STATEMENT OF SIGNIFICANCE

Pediatric cancers are driven by diverse genomic lesions and sequencing has proven useful in evaluating high risk and relapsed/refractory cases. We show that combined whole genome, exome, and RNA-sequencing of tumor and paired normal tissues enables identification and characterization of genetic drivers across the full spectrum of pediatric cancers.

INTRODUCTION

High throughput next generation sequencing (NGS) of pediatric cohorts has provided seminal insights into the genomic landscapes of the major subtypes of childhood cancer. It is now well established that these NGS approaches add significant value by refining or changing cancer diagnoses(1-5), providing prognostic information(3,6), identifying therapeutic targets or markers of therapy resistance(2,3,5,7,8), detecting variants of pharmacogenetic significance(3), and uncovering underlying genetic predisposition(2-5,8,9).

To date, most pediatric NGS studies have focused on patients with high-risk disease, including difficult-to-treat or relapsed/refractory cancers. In many of these studies, patients with newly diagnosed or standard risk cancers are absent or underrepresented. However, many standard risk cancers do not respond or recur following treatment with current best available therapies. Indeed, such is the case for 15 - 20% of acute lymphoblastic leukemia (ALL)(10) or Wilms tumor(11) cases and over 30% of rhabdomyosarcomas(12) or other non-CNS solid tumors. To improve upon these outcomes, it is essential that we comprehensively examine and elucidate the molecular underpinnings of childhood cancer across the full spectrum of presentations.

Each childhood cancer harbors a unique combination of somatic alterations on a background of inherited and *de novo* germline variants. Moreover, novel diagnostic and prognostic subgroups and the full constellation of genetic drivers are yet to be defined for many rare pediatric cancers. As such, an individual pediatric cancer genome could be described as an "*N* of 1" case study for which genome-wide analysis can uncover unique molecular drivers and elucidate how individual combinations of somatic and germline variants influence clinical presentation and response to cancer therapy. Therefore, it is essential that comprehensive genomic data are generated and

systematically investigated if we are to fully capitalize on the potential of precision medicine across pediatric cancers, including those that are common as well as those that are rare.

Prior studies using distinct sequencing platforms have demonstrated that a genome-wide approach is necessary to enable full discovery of novel driver variants in pediatric cancers(1,5,8,13-15). Towards this end, we developed a three-platform sequencing pipeline that includes whole genome sequencing (WGS), whole exome sequencing (WES) and RNA sequencing (RNA-Seq) of paired tumor and normal samples. This three-platform pipeline has been validated on a retrospective cohort of highly selected high-risk pediatric cancer cases harboring known genomic alterations as shown by classical molecular assays. Furthermore, it greatly improved the accuracy of detection of genomic alterations, obviated the need for validation testing of somatic and germline variants through orthogonal approaches, and facilitated discovery of novel oncogenic processes(14).

Here we present data from “Genomes for Kids” (G4K), a prospective non-therapeutic three-platform sequencing study of 309 pediatric cancer patients, unselected for tumor type or stage, treated at St Jude Children’s Research Hospital. The aims of this study were to: 1) demonstrate the utility of comprehensive whole genome, exome, and transcriptome sequencing of paired tumor and normal samples for patients across the spectrum of standard risk to high risk cancers; 2) show how integrating data from multiple sequencing platforms can elucidate the functional impacts of difficult-to-interpret variants; 3) analyze rare genomic findings in *N* of 1 cases and show how these findings inform understanding of tumor biology and, when possible, patient care; and 4) discover novel mechanisms driving a diverse array of childhood cancers.

RESULTS

Patient enrollment

From August 2015 to March 2017, 365 pediatric cancer patients were approached for enrollment in G4K (NCT02530658), a non-therapeutic study of three-platform sequencing of paired tumor and normal samples. Three hundred nine (85%) agreed to participate, 53 (15%) declined and three were later removed from the study (**Fig. 1A**). Race/ethnicity was the only variable that significantly correlated with declining enrollment, with families of black children more likely to decline compared to families of non-Hispanic or Hispanic white children, $p < 0.001$, as we have reported elsewhere(16).

Forty-seven patients did not undergo tumor biopsy for safety reasons or because biopsy was not considered clinically indicated. Nine patients did not have sufficient tumor DNA or RNA to complete three platform sequencing. Thus, 253 of 309 (82%) enrolled patients had their tumors examined using WGS, WES and RNA-Seq. Nine of 309 patients' families (3%) declined the return of germline results, leaving 300 who underwent analysis of germline samples using WES and WGS, followed by in depth evaluation and reporting of 156 cancer predisposition genes. Study participants included 166 males and 143 females with an average age at cancer diagnosis of 7.4 years (range: 4 days to 25.7 years, **Fig. 1B**) (**Supplemental Table S1**).

At the time of G4K enrollment, 262 patients (85%) had newly diagnosed cancers and 47 (15%) had relapsed or refractory disease (**Fig. 1C**). The spectrum of cancers in the G4K cohort was similar to that observed in the NCI SEER registry (**Fig. 1D**), except for Hodgkin and non-Hodgkin lymphoma, which were underrepresented, and leukemia and retinoblastoma, which were overrepresented. One hundred twenty-eight patients (41%) had hematological malignancies of 28 subtypes, 97 (31%) had brain tumors of 27 subtypes, and 84 (27%) had non-CNS solid tumors of 26 subtypes. Forty-five patients (15%) had 18 very rare tumor types,

defined here as tumors present in fewer than 2 cases per million annually in the United States (**Fig. 1E**). Among these 18 tumor types, only craniopharyngioma(17) and mixed phenotype acute leukemia(18) have been studied in enough detail to provide an initial understanding of associated somatic alterations. Thus, the ability to examine the impact of genomic lesions in an *N of 1* context is of paramount importance to understand the biologic basis and therapeutic targets in these very rare tumors.

Overview of somatic alterations

Tumor samples were evaluated using 45X PCR-free WGS and 150X WES from DNA and 100 million RNA-Seq reads from total RNA. Paired germline samples were evaluated using both WGS and WES. Twelve hundred genes known to play a role in the pathogenesis of cancer were interrogated using tumor genomic data. Genes were considered in the context of each patient's tumor type and prioritized for review, as previously described(19). Given the potential effects of structural events and gene fusions on protein expression and function, we reported novel events if there was strong sequence support and the structural event or gene fusion involved genes of potential relevance to cancer. We detected somatic single nucleotide variants (SNVs), small insertions/deletions (indels), loss of heterozygosity (LOH), structural variants (SVs) including fusions, enhancer hijacks, internal tandem duplications (ITDs), and copy number alterations (CNAs) using automated computational pipelines followed by analyst curation(14). Among the SNVs and indels observed on both WGS and WES platforms, 41% had a variant allele fraction (VAF) below 0.2 and 15% had a VAF below 0.1, revealing a large set of sub-clonal variants, including P/LP variants in both SNV and indels, using this approach (**Supplemental Figs. S1A, B**).

All variants were reviewed by a committee of computational biologists, pathologists, oncologists, geneticists and genetic counselors. Reportable P/LP alterations included SNVs (22%); indels

(10%); gross chromosomal losses, gains and LOH (33%); sub-arm copy (focal) number abnormalities (20%) and SVs/gene fusions (44%). Overall, we reported a mean of three pathogenic or likely pathogenic (P/LP) somatically-acquired sequence variants per case (range 0-14) in addition to ploidy alterations, such as gross chromosomal gains and losses and chromosome arm-level regions of copy neutral LOH (CNLOH). Two brain tumors had no reportable P/LP findings despite pathology review indicating adequate tumor tissue. The prevalence of variants deemed P or LP in hematological malignancies, brain tumors, and non-CNS solid tumors, affected by diverse mutational mechanisms, were consistent with other recent pediatric cancer genomic studies(8,14,15,20-22) (**Fig. 2A, Supplemental Table S2**).

Identification of gene fusions, enhancer hijacks, microdeletions

SVs causing gene fusions or enhancer hijacking are important drivers of pediatric cancers(23-25), yet they are challenging to detect by WES as SV breakpoints are most often located in non-coding regions of the genome. Consistent with this finding, we showed previously that inclusion of WGS in the study of pediatric cancer genomes significantly improves the detection of driver gene alterations when compared to WES alone(14). Using the three-platform sequencing approach, we identified in-frame gene fusions in 90 tumors (36%) representing 44 distinct gene-pairings and 34 distinct fusion driver genes of which 23 were diagnostic for a specific cancer type or subgroup. Thirty of the 34 conferred a clear or potential diagnostic, prognostic or therapeutic utility (**Fig. 2B, Supplemental Figs. S2 and S3, Supplemental Table S2**). For example, brain tumor SJB030081, originally classified as a high-grade glioma, was found to harbor an *MN1-CXCC5* gene fusion and thus reclassified as a CNS high-grade neuroepithelial tumor with *MN1* alteration, an entity only recently described(26). Five of the rare fusions shown in **Fig. 2B** (shown in red) were in patients with very rare tumor types (as shown in **Fig. 1E**).

In an additional 21 tumors (8%), combined WGS and RNA-Seq analysis enabled detection of 10 distinct enhancer hijacking translocations, wherein an SV brings a transcriptionally active locus into close proximity to an oncogene thereby driving its expression. We correlated outlier oncogene expression with SV breakpoints from WGS data to facilitate the accurate detection of enhancer hijacking events, which ranged from 0-716 kb up or downstream of the target oncogene with outlier expression (see Methods, **Supplemental Fig. S4, Supplemental Table S3**). Enhancer hijacks included well-characterized events such as *IGH@-CRLF2*, *TCR@-LMO2*, *IGH@-DUX4*, *IGH@-EPOR*, and *DDX31@-GFI1B*. In addition, there were less-well-characterized enhancer hijacks such as two instances of *CDK6@-MECOM* in acute myeloid leukemia, which may have a negative prognostic impact(27), and a novel *TLX3*-activating translocation in a T-acute lymphoblastic leukemia (T-ALL) sample, as described below (see below, "Disease relevance of novel somatic variants").

Acute leukemias are susceptible to small microdeletions, resulting from off target recombinase activating gene (RAG)-dependent effects(28,29). Detection of these deletions can be of prognostic significance, as is the case with *IKZF1* in B-ALL, where intragenic deletions are associated with a poorer outcome(30). However, intragenic microdeletions can be difficult to detect using WES because exons rarely capture deletion breakpoints and their identification must rely on subtle changes in depth of coverage(31,32). Consistent with this notion, we previously observed that single nucleotide polymorphism (SNP) array or WES have limited power for detecting focal and exon-poor CNAs due to insufficient physical space for robust detection of read-depth changes(14,33). Using WGS data, we detected small intragenic deletions involving as few as one or two exons in cancer-relevant genes in 38 tumors (15%), with all but six being leukemias (**Supplemental Table S4**). Twenty-six genes were affected, including those expected(28), such as *BTG1*, *CDKN2A*, *ETV6*, *RAG1*, *TCF4*, *IKZF1*, and *TP53* among the most commonly involved. Several clinically relevant genes that are less commonly

observed as targets of microdeletion, including *CREBBP*, *SH2B3*, *USP9X*, *FBXW7*, and *NR3C2*, were also impacted. The majority of these microdeletions (38 of 53 total events; 72%) involved loss of a single gene copy and thus would have been difficult to detect using WES.

Mutation signatures and etiology of pediatric tumors

The whole genome mutational landscape of a tumor records its natural history and reflects the environmental and endogenous exposures that have contributed to tumor initiation and progression(34,35). To elucidate the mutational landscape of pediatric cancers, we evaluated WGS tumor data for the relative proportions of mutation signatures reported by Alexandrov(36) (**Supplemental Table S5**). In addition to well-known mutational processes such as spontaneous deamination (Signature 1) evident in nearly every patient, Signatures 2 and 13 reflecting activation induced cytidine deaminase (AID) and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) activity were present in several of B-ALL cases(37,38); Signatures of ultraviolet radiation exposure were present in four B-ALL samples and a cutaneous melanoma (see also(15)) and three tumors exhibited signatures 6 and 15, indicating mismatch repair (MMR) deficiency as well as signature 10, which is associated with mutated DNA polymerase epsilon (POLE). Six tumors harbored high levels of signature 18, thought to arise from DNA damage induced by reactive oxygen species (ROS) with one tumor exhibiting bi-allelic loss of *MUTYH*, the glycosylase that executes the first step in repair of ROS-induced mutations. The roles of the MMR deficiency, and POLE and ROS signatures in disease pathogenicity are described further below (see "Disease relevance of germline variants").

Disease relevance of novel somatic variants

Most pediatric cancer genomes harbor a limited number of somatic alterations, many of which are non-recurrent making it difficult to ascertain pathogenicity. Visualization of these variants in the context of large-scale public data was essential to classify some of these challenging *N* of 1

events. We illustrate this process with two examples. The first case, SJTALL030071, is a T-ALL that harbored a translocation t(5;8)(q35q24) linking an intergenic region on 8q24, 1 Mb distal of *MYC*, to an intergenic region 29 kb distal to *TLX3*, a known driver of T-ALL(39). The copy number profile of this tumor showed an 18 Mb duplication of the 8q24->8qter region that did not include *MYC* (**Fig. 3A**); but did include the NOTCH *MYC* enhancer(N-Me)(40) that is known to activate *MYC* in T-ALL. Indeed, N-Me activity was confirmed by the high level of enhancer RNA and *MYC* expression in this tumor. The translocation juxtaposed N-Me 29 kb upstream of *TLX3* leading to elevated *TLX3* expression (**Fig. 3B**). Moreover, using SNP markers in the DNA at the *TLX3* locus, we demonstrated allele-specific expression (ASE) in the RNA, consistent with activation by a cis-acting regulator (**Fig. 3C**). Consistent with these findings, SJTALL030071 clustered by tSNE analysis among other *TLX3*-driven T-ALLs from the National Cancer Institute-Therapeutically Applicable Research to Generate Effective Treatments (NCI-TARGET) cohort (**Fig. 3D**). Altogether, these data suggested mechanistic similarity to known enhancer hijack events linking *TLX3* to T-cell receptor enhancer loci(39,41) and accordingly we classified the translocation as LP.

The second case, SJBALL030052, is a B-ALL with a complex structural variant that exhibited DNA and RNA evidence of a novel fusion including exon 2 of *ETV6* with exon 2 of *FOXO3* (**Fig. 3E**). The impact of this fusion was not initially clear as it could conceivably result in *ETV6* loss of function (LOF) or in a gene fusion functionally similar to *ETV6-RUNX1*. To gain further insights, we compared the RNA-Seq gene expression profiles between our B-ALL sample and the publicly available RNA-Seq profiles from 1,988 other childhood B-ALL cases(42). SJBALL030052 clustered with the *ETV6-RUNX1* subgroup (**Fig. 3F**), suggesting that the fusion impacted gene expression similarly to *ETV6-RUNX1*. We thus classified the novel fusion as LP, which supported this patient's clinically determined standard risk classification.

Across all 253 tumors, 65 (25%) harbored a total of 89 genetic alterations that were considered rare or unreported in the tumor type being investigated (**Supplemental Table S6**). For example, we found *AKT1* activating variants in two T-ALL patients, SJTALL030064 and SJTALL030134. *AKT1* represents a targetable oncogene in epithelial cancers but it is only very rarely altered in T-ALL and its role and efficacy as a therapeutic target have yet to be investigated in this cancer type. These rare events were often suggestive of unusual mechanisms of activation of an oncogene or signaling pathway. For example, USP9X LOF was found in two cases, and potentially activates JAK/STAT signaling(43). Of these 90 rare or novel events, 23 (26%) were SVs predicted to generate fusions or enhancer hijacks identified by WGS and RNA-Seq analysis. These observations demonstrate that the spectrum of cryptic intergenic events continues to expand through use of these combined non-biased genomic approaches.

Germline cancer predisposing variants

We analyzed 156 cancer predisposition genes using germline WES and WGS data for the 300 patients who consented to return of germline results. This list included 63 genes associated with moderate to high cancer penetrance(9), as well as 93 additional genes, approximately half of which are associated with autosomal recessive cancer predisposing conditions (**Supplemental Table S7**). We classified variants according to the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) 2015 germline variant interpretation guidelines(44). Germline P, LP or variants of uncertain significance (VUS) among the 63 moderate/highly penetrant genes were reported back to providers and patients. For the remaining 93 genes, only P or LP variants were included in the final clinical reports.

We identified 58 germline P or LP variants affecting 29 genes in 55 (18%) of 300 patients (**Fig. 4A, Supplemental Table S8**) and 420 VUS affecting 111 genes in 230 (77%) patients (**Supplemental Table S9**). The prevalence of P/LP variants ranged from 10% for patients with

hematologic malignancies to 40 - 50% for those with retinoblastoma and other solid tumors (**Fig. 4B**). Thirty-two (55%) of the germline P/LP variants affected genes not generally associated with the patient's tumor type, such as a germline mutation in *WT1* in a patient with B-ALL (SJBALL030057) or a germline mutation in *BRCA2* in a patient with a diffuse intrinsic pontine glioma (SJHGG030328, **Supplemental Table S8**). Therefore, if targeted germline gene panels relevant to the patient's tumor type had guided testing, these variants might have escaped detection as many of the panels would not have included the affected genes.

Disease relevance of novel germline variants

An integral component of our germline variant pathogenicity classification involved simultaneous review of paired tumor-normal data to determine the molecular impacts of germline variants on RNA splicing and expression, tumor mutation signatures and tumor mutation burden (TMB). For example, transcriptome data from Ewing Sarcoma, SJEWS030332, harboring a novel *BAP1* intronic variant at the -3 position of exon 5 (NM_004656.3: c.256-3C>A), revealed evidence of intron retention in the tumor relative to other Ewing Sarcoma samples in the study. Fisher's Exact test showed a significant difference in number of variant-bearing RNA-Seq intronic reads relative to PCR-free tumor WGS ($p=0.047$) (**Fig. 4C**). Intron retention, unveiled by the use of tumor RNA data, provided sufficient evidence to classify this novel germline variant as LP.

A patient with B-ALL, SJBALL030144, presented with café au lait macules but no coding mutations to explain this clinical phenotype. Analysis of tumor RNA data revealed that a germline *NF1* variant at the +3 position of exon 45 (NM_000267.3: c.6858+3A>G) caused skipping of exon 45, which is predicted to lead to out-of-frame translation of the NF1 protein (**Fig. 4D**). This variant was classified as LP. The opposite conclusion was obtained for a germline *APC* variant (NM_000038.5: c.449A>G) in patient SJST030310. Analysis at an external clinical laboratory predicted creation of a *de novo* splice site with subsequent LOF;

however, review of tumor transcriptome data provided no evidence of altered splicing, and we thus classified this variant as a VUS (**Supplemental Fig. S5**).

TMB and mutation signatures derived from WGS were used to establish the roles of germline variants in generating the molecular phenotypes observed in some tumors. Tumors were classified as hypermutators based on a TMB >10 mutations per Mb and ultra-mutators with >100 mutations per Mb(45). Two cases (SJHGG030335, SJHM030291) harbored germline biallelic *PMS2* pathogenic variants leading to tumors that exhibited TMB and mutational signatures consistent with MMR deficiency (**Supplemental Table S5**). SJHGG030335 harbored >100 mutations per Mb due to an acquired *POLE* S459F pathogenic somatic variant. The *POLE*-related mutational signature was also exhibited by this tumor.

Finally, SJST030211, a squamous carcinoma of the lip, exhibited a hypermutator phenotype corresponding to COSMIC signature 11, which is linked to temozolomide treatment (**Supplemental Fig. S6A,B**). Consistent with this finding, this patient had received prior therapy with temozolomide for a low-grade glioma and had no detectable mutations in MMR genes in the germline or the squamous carcinoma. Thus, the mutator phenotype was caused by therapy, with this information obviating the need for follow-up germline testing for the patient and family.

As more children with cancer undergo gene panel or multiplatform sequencing, an increasing number of pathogenic germline variants are being identified in genes not generally associated with the patient's tumor type, and in some cases, these variants are associated with adult-onset conditions or autosomal recessive cancer predisposition syndromes(4,5,9,22,46). Nevertheless, it remains poorly understood whether or how these germline variants contribute to the pathogenesis of pediatric cancers. Therefore, we reviewed all germline P/LP variants in the context of each patient's tumor type to determine whether the germline variant might have

played a causal role based on the molecular phenotypes observed in the tumor. We considered a germline variant relevant to development of the child's tumor if the gene had a known association with the child's tumor type, or if there was specific molecular evidence supporting a functional consequence of the mutation in the tumor. If neither of these criteria were met, the relevance of the variant in the tumor was considered to be unknown (**Supplemental Fig. S7**).

Using this scheme, 32 of 58 (55%) germline P/LP variants affecting 15 genes were characterized as relevant to tumor formation ("Disease Related", **Supplemental Table S8, Fig. 5**). Most of these genes have known relationships with pediatric cancer, such as *RB1* in retinoblastoma (RB), *NF1* and *PMS2* in glioblastoma (GBM), and *PTCH1* in medulloblastoma. Examination of tumor WGS and RNA-Seq data, protein expression and the literature enabled classification of disease relevance in several *N of 1* cases, illustrated in the following examples.

First, we observed a missense germline *TP53* variant, (A161T), in patient SJNBL030203 with NBL. Although prior studies have suggested that this variant is damaging with a dominant negative LOF effect(47-49), NBL occurs only very rarely (~1%) in individuals with pathogenic germline *TP53* variants(50). Further, like most NBL(51), this patient's tumor retained the wild-type *TP53* gene copy. However, examination of tumor RNA-Seq data revealed expression only of the variant allele (**Fig. 6A**). Together these data suggest that there is transcriptional silencing of the wild-type gene copy, a mechanism not yet described in NBL, and we considered this germline variant relevant to the child's tumor.

Patient SJRB030050 with RB harbored a germline *MUTYH* founder variant (G396D, **Fig. 6B**) that was rendered homozygous in the tumor through CNLOH. The TMB was in the upper quartile among all RB tumors in the G4K study, as well as a larger set of RB tumors evaluated

through the Pediatric Cancer Genome Project (PCGP) (**Fig. 6C**). Notably, over half of this tumor's mutations were attributable to the ROS Signature 18 (**Fig. 6D**). These features indicate that the loss of *MUTYH* function contributed to the mutational processes in this tumor. As a result, the germline *MUTYH* variant was classified as relevant to RB development in this patient. In two other patients harboring the same germline *MUTYH* founder mutation (**Supplemental Table S8**), the variant was considered of uncertain relevance to disease because there was no loss of the wild-type allele and no ROS mutation signature in their tumors.

Two patients harbored a single heterozygous mutation in one of the MMR genes characteristic of Lynch Syndrome (LS; also known as hereditary non-polyposis colon cancer). Patient SJHGG030336 with GBM harbored a germline *MSH2* variant (N653fs) and patient SJBT030067 with an unusual adenocarcinoma of the pineal region of the brain harbored a *PMS2* variant (S46I). Neither tumor exhibited mutation or loss of the respective wild-type gene copy. Nevertheless, the *MSH2*-mutant glioblastoma (SJHGG030336) was hypermutated (**Fig. 6E**) and exhibited a mutation signature associated with microsatellite instability (MSI, **Fig. 6F**), consistent with the LS phenotype. Based on the high TMB and mutation signatures, immunohistochemical staining of this child's tumor was performed, revealing absent MSH2 and MSH6 expression (**Fig. 6G, top**), and confirming a deficiency in MMR. The germline *MSH2* N653fs variant was thus deemed relevant to this child's GBM. In contrast, the pineal adenocarcinoma in patient SJBT030067 did not exhibit hypermutation (**Fig. 6E**) or the mutation signature of MSI (**Fig. 6F**) and it retained PMS2 expression (**Fig. 6G, bottom**). Therefore, the disease relevance of the germline *PMS2* variant to development of this child's adenocarcinoma remained uncertain.

Finally, patient SJNBL030339 with NBL harbored a pathogenic germline variant in *SMARCA4* with focal deletion of the wild-type allele observed in the tumor (**Fig. 5**). The oncogenic potential of germline *SMARCA4* variants is known to predispose to small cell carcinoma of the ovary and

less commonly to rhabdoid tumor(52), but it has not been linked to NBL. However, our finding raises the possibility that *SMARCA4* represents a target for mutational inactivation in NBL. Consistent with this notion, *SMARCA4* is expressed in neural tissues and somatic bi-allelic *SMARCA4* variants are present in 1% of NBL tumors(53). Further, the literature includes two cases of NBL with pathogenic germline *SMARCA4* variants(4,54). Taken together, these data strengthen the association between germline *SMARCA4* variants and predisposition to NBL.

Management implications resulting from genomic findings

Although the G4K study was non-therapeutic by design and thus not intended to match patients to a targeted therapy, we sought to investigate whether genomic findings obtained from three platform sequencing would inform diagnosis, risk stratification, cancer treatment and/or genetic counseling of the patient and family(6,55,56). We deemed variants as therapeutically actionable or potentially actionable if they were classified as P/LP from a somatic perspective and they or their downstream pathways could be targeted(6). To make these determinations, we used available evidence(46,57,58), including U.S. Food and Drug Administration approved targeted therapies, eligibility for treatment on a clinical trial based on NGS results and other professional guidelines or associated information (<https://www.oncokb.org/>; <https://civicdb.org/home>).

In total, 218 of 253 patients (86%) who underwent sequencing of paired tumor and normal tissues had at least one finding that was diagnostic (53%), prognostic (57%), therapeutically-targetable (25%), involved in cancer predisposition (18%) or some combination of these features. (**Fig. 7A, B; Supplemental Table S10**). Among the somatic alterations, the preponderance of targetable abnormalities included gene fusions or hotspot mutations in kinases including *BRAF*, *ALK*, *MET* and *ABL1*. We also detected several indirectly targetable mutations/fusions affecting genes upstream of the JAK-STAT pathway involving *EPOR*, *CRLF2*, *SH2B3* and *USP9X*. Fusions of *EPOR* and *CRLF2* and truncations of *SH2B3* and *USP9X* are

associated with Philadelphia chromosome-like B-ALL(57,59), the treatment of which with JAK1/2 inhibitors is under investigation (NCT03117751, NCT02723994).

At the time of diagnosis, the majority of pediatric cancer patients, including those in the G4K study, are placed on IRB-approved clinical trials. However, 78 G4K patients with sequenced tumors presented with relapsed or metastatic tumors for which there was no clinical trial available, or they developed metastatic, relapsed or refractory disease during the course of the study. Thus, approximately one third of the patients were eligible for a change in therapy, including an NGS-directed agent. Thirty-two (41%) of the tumors in this relapsed/refractory group harbored one or more targetable or potentially targetable lesions or a targetable mutation signature. Twelve patients (38%) received a targeted agent matched to their tumor's genetic lesion or mutational signature (**Supplemental Table S11**). Five of these 12 patients responded to the genomics-directed therapy (one patient with AML [complete response], one with melanoma [partial response], two with glioblastoma [stable disease, SD], and one with craniopharyngioma [SD]) (**Fig. 7C**). The two patients whose glioblastomas exhibited mutational signatures consistent with mismatch repair deficiency were treated with checkpoint inhibitors with one of these two surviving for two years under this therapy, while exhibiting no significant side effects. Two patients remain alive at the time of writing: SJAML030286, whose AML harbored a somatic *FLT3* internal tandem duplication and was treated with sorafenib and gilteritinib-containing regimens for a total of 12 weeks followed by allogeneic stem cell transplantation; and SJBT030073, whose multiply recurrent craniopharyngioma harbored a somatic *PIK3CA* mutation and was treated with everolimus for 172 weeks. This patient's tumor progressed and was subsequently partially resected with sequence analysis of the resected tumor showing loss of the *PIK3CA* variant.

All participants with P/LP germline variants have undergone genetic counseling and first-degree relatives have been offered clinical evaluation and targeted genetic testing; more distant family members have been encouraged to pursue counseling in their home communities. Although cascade testing is still ongoing, 27 of 77 (35%) tested individuals from 31 families have been found to harbor a cancer predisposing germline variant (**Supplemental Table S8**) and all have been provided with recommendations for cancer surveillance and when appropriate, risk reducing measures. To date, 19 of 58 germline P/LP variants (33%) have been confirmed as inherited, while 12 (17%) are *de novo* in origin. The remaining 27 are of unknown inheritance.

Comparison to gene panels

We next sought to determine what proportion of the events found by the three-platform sequencing approach would also be detected by commercially available gene panels. For this analysis we selected four commonly used somatic panels: Foundation One CDx, Foundation One Heme, Oncomine v3, and Oncokids Hotspot. All four panels detect coding SNVs and indels, including exonic ITDs and focal copy number alterations (CNAs). For a defined set of genes, Foundation One CDx detects common intronic translocation breakpoints in DNA and the other panels detect fusion transcripts in cDNA. For comparison of novel gene fusions, we required that the panel include only one partner gene of the fusion pair discovered in our data set (see Methods, “Comparison to gene panels”, **Supplemental Table S12-14**, for further details).

We observed that 42 - 84% of the evaluable P/LP SNVs/indels/ITDs/fusions/SVs and focal CNAs could have been detected by one or more of the panel designs (**Supplemental Tables S12,13**). Oncomine, applied to pediatric hematologic malignancy cases, covered the G4K variants least efficiently. This is not surprising since the panel is optimized for evaluation of adult solid tumors. The pediatric-specific Oncokids panel fared better covering 65% and 74% of

reported abnormalities for brain/CNS tumors and hematologic malignancies, respectively. The best performing panel was Foundation Heme when applied to pediatric hematologic malignancy cases, covering 84% of reported abnormalities. Confining our analysis to only include clearly targetable mutations (i.e., omitting potentially targetable mutations such as KRAS G12D, EWSR1-FLI1 and others as defined in **Supplemental Table S2**), panel coverage ranged from 39 to 85% with OncoPrint applied to pediatric hematologic malignancies detecting the fewest alterations and Foundation CDx applied to solid and brain tumors detecting the most (**Supplemental Table S14**).

On a per patient basis, between 36 - 69% of patients had at least one reported mutation through G4K that was not covered by one of these panel designs (**Supplemental Tables S13, S14**). This number includes abnormalities with a functional impact on the protein but of no known clinical significance. Considering only those variants with clear clinical impact, between 18 - 30% of patients had at least one diagnostic, prognostic, therapeutically relevant or cancer predisposing mutation that was not covered. Interestingly, two of the 12 patients with relapsed or refractory cancers who received a genomics-specified therapy harbored variants that would not have been detected by these panels. These include patient SJMEL030083 with a metastatic melanoma harboring a *MAP3K8-GNG2* fusion (treated with the MEK inhibitor trametinib) and patient SJBT030076 whose clear cell meningioma harbored an *EP300-KLF17* fusion (treated with the EGFR inhibitor erlotinib) (**Supplemental Table S11**).

DISCUSSION

Through the G4K study, we performed comprehensive WGS, WES and transcriptome sequencing of tumor and/or paired normal samples from 309 prospective unselected children with cancer to quantify the prevalence and spectrum of genomic variants and evaluate the potential benefits of a three-platform sequencing approach. Several recent reports have focused on cohorts enriched in children with high risk, relapsed and refractory cancers(1,3,8,57,58,60,61). The G4K study intentionally differed from these others in that it was designed to investigate an unbiased cancer cohort, including patients with newly diagnosed standard risk tumors, as well as those with more aggressive forms of disease, to specifically ask whether novel insights into the biology of cancer can emerge from comprehensive sequence analysis of all pediatric cancers.

Incorporation of whole genome DNA sequencing enhanced the identification of clinically relevant lesions that are detected inefficiently or not at all by other genomic platforms. WGS detected inter- and intragenic SV breakpoints, which demarked the location of translocations and large deletions on whole chromosome scales. Translocations that activated oncogenes through enhancer hijacking with chromosomal breakpoints up to more than 750 Kb away from the target oncogene were present in 8% of cases. On a smaller scale, WGS detected intragenic microdeletions affecting one or two exons in 15% of tumors, some of which may not be detectable by exome-based copy number analysis, as shown in our previous study(14). Moreover, the passenger mutations in WGS identified the mutational processes supporting the role of germline lesions in MMR (*MSH2*, *PMS2*) and base excision repair genes (*MUTYH*) that contributed to the pathogenesis of several tumors. Taken together, up to one third of tumors in the G4K study were impacted by oncogenic events detected most sensitively by WGS. Recent results demonstrate that topologically associated chromatin domains(62) can be disrupted by focal copy number variation leading to dysregulated expression of oncogenes and tumor

suppressors located in cis, often at long distances from the genomic event(63,64). These data point toward an increasingly important role in the near future for WGS combined with transcriptome sequencing in the clinical evaluation of patient tumor genomes.

Eighty six percent of patients had at least one finding that was diagnostic, prognostic, targetable, or indicating an underlying germline predisposition. One quarter of the tumors analyzed harbored a possible therapeutic target, excluding cases wherein MEK inhibitors would be an option. Benefit from MEK inhibitors, used downstream of mutant *KRAS*, *NRAS* and *NF1*, is more difficult to predict, but including MEK inhibitors, our potentially targetable group would comprise 43% of all tumors tested. While this proportion falls within the range of recent studies(4,5,8), it is notable given that the majority of patients on the G4K study had newly diagnosed standard risk cancers, which might be expected to harbor fewer variants when compared to high risk or relapsed/refractory cases. Potentially targetable abnormalities consisted mostly of JAK/STAT pathway mutations in B-ALL that can be treated with ruxolitinib or other JAK inhibitors; high TMB samples that can be treated with pembrolizumab, ipilimumab or additional check point inhibitors; and kinase fusions including *BRAF* in low grade glioma, which may be treated with tyrosine kinase or MEK inhibitors. The proportion of patients who respond to these or other therapies remains to be determined and is an active area of investigation.

During the course of the G4K study, 78 patients whose tumors were sequenced presented with or developed metastatic, relapsed or refractory disease with almost half of the tumors harboring potentially targetable lesions. Therapy was changed for 12 patients based on tumor genomic data, with one patient moving on to curative allogeneic stem cell transplantation, and four patients exhibiting prolonged disease stabilization. Recently the Zero Childhood Cancer Program reported on 38 patients receiving a genomics-specified targeted therapy, with 31% demonstrating clinical benefit(22), a proportion similar to ours. Nevertheless, despite favorable

clinical outcomes in a limited number of patients, overall responses were modest across both of these studies. Together, these findings highlight that we still do not understand the full spectrum of genomic lesions that drive therapy response in most children with cancer. These findings support our premise that the collection and interrogation of comprehensive genomic information is critical if we are to further push the boundaries of cure.

Revealing an inherited cancer predisposition can impact patient management by informing genetic counseling, enabling familial genetic testing, facilitating implementation of cancer surveillance and cancer risk reducing measures, and directing cancer treatment. Our screening through G4K uncovered germline P/LP variants in 55 patients of whom almost two thirds would not have been detected based on routine clinical indications for genetic testing. Importantly, simultaneous assessment of tumor and germline genomes, including features such as TMB and mutation spectrum, and allele-specific expression, improved variant classification in several cases. Indeed, we found corroborating evidence in the tumor that at least half of the germline P/LP variants we reported were likely to be relevant to the development of the child's tumor.

Gene panels designed to match patients with currently available targeted therapies offer a rapid turn-around time, low expense, deep sequencing coverage, and sparing of tissue when limited biopsy material is available – all valuable characteristics in the clinical setting. Moreover, the trend toward adapting panels to capture cDNA addresses the need to detect fusion transcripts, allowing for the discovery of novel fusion partners of the more commonly involved oncogenes(65). Thus, for routine standard of care, comprehensive gene panels address the medical need of the majority of patients. Nevertheless, there is much yet to be learned about childhood cancer. Among our set of 12 patients with relapsed or refractory cancers whose therapies were changed based on tumor genomic data, two received therapy as the result of novel alterations that would not have been detected by the any of the panels examined. Further,

the relevance of a comprehensive view of the mutational landscape in informing understanding of tumorigenesis and management, even in the diagnostic setting, should not be underestimated. When evaluating the yield of gene panels in the G4K cohort, approximately one in five patients harbored a clinically relevant mutation that we conservatively estimated would have remained undetected using one of the panels examined. For the G4K patients sequenced at diagnosis, it remains to be determined what impact these events will have on overall outcomes.

Despite its potential benefits, comprehensive genomic profiling, such as that reported herein, is currently beyond the scope of most cancer clinical services for a variety of reasons. First, obtaining fresh frozen tissue for three-platform sequencing was not feasible for all patients. For the cancers where only limited biopsy is possible, alternative workflows involving formalin-fixed paraffin embedded samples may need to weigh the benefits of the breadth of WES against the coverage depth of a robust panel design. Second, the infrastructure and computational resources necessary to perform three-platform sequencing are substantial. Although recent innovations in cloud computing and reductions in the costs of NGS instruments and reagents are rapidly making whole genome approaches more affordable, comprehensive genomic profiling will not be standard of care for some time to come. Third, turn-around time is a major challenge to a comprehensive genomics approach in the clinical setting. Throughout the G4K study the entire workflow, from analyte preparation to data analysis, classification, and reporting was under seven weeks for 95% of the cases. Currently turn-around times are under six weeks, and we are investigating improved laboratory and computational methods reduce this still further. Finally, as we recently reported(16), there was a significant overrepresentation of African American patients who declined participation in the G4K study. While all 53 patients were later offered more focused germline testing, only 11 chose to pursue such testing. Thus, disparities exist in the context of cancer genomics and additional efforts are warranted to

understand patients' perspectives and decision making surrounding such testing to enhance future enrollment of diverse populations.

In summary, the G4K study provides evidence that three platform sequencing of tumor and paired normal tissues generates a more detailed picture of the genetic landscape of a tumor, at times revealing clinically relevant information that would go undetected if one used more targeted NGS approaches. As genomic sequencing technologies become less expensive and more widely available, their use will be an important adjunct to gene panels in the evaluation and management of children with newly diagnosed as well as relapsed or refractory cancers.

METHODS

Patient eligibility and accrual

This study was approved by an institutional review board (IRB# Pro00005011) and conducted in accordance with institutional and ethical guidelines. Over 20 months, 918 patients at St. Jude Children's Research Hospital were assessed for enrollment in the G4K study (NCT02530658). Enrollment criteria consisted of availability of a fresh-frozen tumor sample and a paired normal (i.e., germline) sample. Tumor purity was determined by a pathologist using visual inspection of a hematoxylin & eosin (H & E) stained section of the tumor just adjacent to the portion sent for DNA and RNA extraction. For leukemia samples, tumor purity was determined based on a blast count determined by visual inspection of an H & E stained bone marrow section or by flow cytometric analysis. A tumor purity >40% tumor was preferred in order for sequencing. Tumor purity was >40% in all but 16 cases, where it ranged from 23 – 37%. Nevertheless, sequencing successful in each of these cases.

Three hundred sixty-five patients were eligible to enroll. Patients and their parents met with a research nurse, trained by certified genetic counselors, who introduced the study and answered questions. Patients were provided with written materials describing the study and a copy of the consent form to review. Interested patients were scheduled for an informed consent visit during which the research nurse reviewed key concepts, assessed parent and patient understanding and obtained written informed consent. When possible, patients also met with an oncologist, clinical geneticist or nurse practitioner to undergo collection of a full medical history and completion of a physical examination, and with a genetic counselor who obtained the family history and constructed a three-generation pedigree. A positive family history was defined as presence of at least one first- or second-degree relative with cancer diagnosed before age 50, excluding cervical and non-melanoma skin cancers (see **Supplemental Table S15**). This same

definition was used in our prior report of germline findings from the Pediatric Cancer Genome Project(9) and it is very similar to those in other recent reports(66-68).

Nucleic acid extraction and sequencing

For solid tumors, sample adequacy and tumor cell percentage were assessed using a hematoxylin and eosin-stained section from a block of tumor tissue adjacent to the one from which DNA and RNA were extracted. For leukemias, adequacy was based on bone marrow blast count. Tumor tissue was not available for many patients with RB, craniopharyngioma, optic pathway glioma and diffuse intrinsic pontine glioma due to safety concerns around biopsy (see **Supplemental Table S1** for more details).

Nucleic acid extraction, library preparation and sequencing on the Illumina HiSeq 2500/4000 were as described(14) with a single modification. Specifically, in our previous clinical genomics pilot study, WES was performed using the TruSeq DNA LT Sample Prep kit (Illumina Inc., San Diego CA), whereas in the present study it was completed using the Nextera Rapid Capture Exome Kit and the TruSeq Exome kits (both from Illumina). Samples were named according to the following convention: SJ (St. Jude), Disease code (for example RB; disease codes are listed in **Supplemental Table S1**), patient number, sample type (D1 is first diagnostic sample, D2 is second diagnostic sample, R1 is first relapsed sample, G1 is first germline sample, etc.). Sequencing coverage and other statistics are listed in **Supplemental Table S16**.

Post-sequencing quality-control (QC) thresholds established during the pilot phase of our clinical service(14), were as follows: for WGS, $\geq 40\%$ coverage of coding exons at 45X, however $\sim 80\%$ coverage at 30x was acceptable upon the Medical Director's review. For WES, coverage of coding exons was ideally $\geq 65\%$ at 45x, but $\sim 80\%$ coverage at 30x was acceptable upon the Medical Director's review. For RNA-Seq, ideally $\geq 15\%$ of coding exons were covered at 45x, but

20% at 30x was acceptable upon the Medical Director's review. Additional sequencing was performed in some samples in order to meet acceptable coverage QC thresholds.

Variant classification and reporting

WGS, WES and RNA-Seq data were aligned and variants called and annotated using previously published algorithms(19,33,69,70) and automated pipeline infrastructure(14). Genome analysts reviewed variant calls and presented each case to a multidisciplinary tumor board consisting of representatives from Pathology, Computational Biology and Oncology. Since our objective was to report SNVs/indels and CNAs from the somatic and germline context, as well as somatically acquired SVs, we adopted a unified reporting nomenclature that encompassed every variant type. As a convention, in referring to regional or focal copy number changes, we use CNA in the somatic context, and CNV in the germline context. We classified germline SNVs and indels according to the ACMG 2015 guidelines(44) and subsequently adopted the same nomenclature for other variant types. We reported germline P, LP and VUS found among 63 high-risk cancer predisposition genes, including those recommended by ACMG v2.0(71) and those for which clinical management recommendations exist or are under development(44), as well as P/LP variants in 93 additional cancer predisposition genes. Germline CNVs were assessed for their functional impact on the gene of interest. If a CNV caused a loss of function, we applied the PVS1 tag(72) and if it was rare or absent from databases such as DGV (<http://dgv.tcag.ca/dgv/app/home>), we also attached the PM2 tag, allowing us to classify these variants as P/LP in keeping with germline SNV/indel calls.

Somatic variants with a clear or likely impact on the function of a cancer-relevant gene were classified as P or LP, respectively, and those with an uncertain impact were classified as VUS. Somatic variants classified as VUS were not included in clinical tumor reports. When assessing the pathogenicity of somatic SNVs/indels, we considered multiple lines of evidence obtained

using functional prediction algorithms and literature mining, as well as recurrence in the PCGP(20) and NCI-TARGET(15) databases, other pediatric cancer mutation data in the St. Jude PeCAN portal(73), and adult cancer data from the Catalogue of Somatic Mutations in Cancer (COSMIC)(74). Whenever possible, we used tumor RNA data to establish the functional impact for novel SVs by seeking evidence of truncation or in-frame gene fusion, and for gene amplification or enhancer hijacks, we used these data to examine gene expression.

We based our assessment criteria for clinical actionability on the system described by ACMG/ASCO/AMP(56,75). For SNVs/indels we called any variant with Tier IA/B or tier IIC as actionable as these comprised diagnostic, prognostic and therapeutically-relevant lesions with a high level of supporting evidence that an oncologist might reasonably act upon. Several lesions that did not meet this stringent threshold were mostly placed in Tier IID and labeled as "potentially actionable" (**Supplemental Table S2**). For CNAs, we considered Tier 1A/B and 2 variants as actionable(75) and applied these same assessment criteria to SVs.

Bioinformatics analysis

Bioinformatics analysis and variant review were as described(14). Briefly, sequence reads were aligned using BWA(76) for DNA or BWA and STAR via our Strongarm pipeline(77) for RNA. Sequence variants were called using Bambino(69), DNA SVs using CREST(70), RNA SVs including ITD using CICERO(78), a local assembly-based algorithm that integrates RNA-seq read support with extensive annotation for candidate ranking and available online at: https://www.stjude.cloud/tools/rapid_RNA-Seq), and CNVs and allelic imbalance with CONSERING(33). Variants were annotated using the Medal Ceremony/PeCanPIE pipeline(19) (available online at: <https://pecan.stjude.cloud/pie>). We estimated TMB by counting all exonic and UTR variants that passed manual review by a genome analyst in addition to high-quality intronic and non-coding somatic variants falling outside of repeat regions. For genome-wide

calculations, we used only somatically acquired high quality variants whose Fisher's Exact Test p-value for somatic origin was <0.05 . To calculate mutations per Mb of DNA, we took all high quality somatic variants from WGS and divided by 1445 Mb - the total amount of genome capable of generating a mutation call consisting of Tier 1 (coding exons, splice regions and UTRs): 108,721,345 bp, Tier 2 (potential regulatory regions): 163,138,648 bp, and Tier 3 (intergenic and intronic regions): 1,173,180,850. Tier 4 (repeat regions): 1,448,043,873 were omitted from the calculation since our mutation calling pipeline masks these regions. For mutational burden in exome only regions, we used 108.7 Mb as the denominator - the size of Tier 1 regions listed above. B-ALL and T-ALL 2D t-SNE distributions used data and methods described previously by Gu et al. (2019)(42) and Liu et al. (2017)(41). All additional analyses used standard parameters unless stated otherwise. Gene expression was quantified using the Gencode 75 gene model and HTSeq (version 0.11.1)(79) and normalized between samples using the DESeq2 (version 1.26) variance stabilizing transformation function(80). SigProfilerSingleSample was used to test for the presence and abundance of the COSMIC v3.1 Mutation Signatures(36), as described(45). Briefly, samples with 400 or more mutations (485 samples) were analyzed for 46 of the COSMIC signatures (excluding 23 COSMIC signatures which were rarely detected and manually found to be spurious in each positive case. Samples with fewer than 400 mutations (583 samples) were analyzed for a core set of 13 signatures (1, 2, 3, 5, 7a, 7b, 7c, 7d, 8, 13, 18, 36, and 40) which could be reliably detected in low mutation burden samples and common in pediatric cancers (**Supplemental Table S5**).

Analysis of putative enhancer hijacks

SJTALL030071 harbored a non-canonical interchromosomal translocation juxtaposing the N-Me (**NOTCH MYC** enhancer) enhancer to the vicinity of TLX3 caused upregulation of the gene. To investigate further the possibility of activation of TLX3 by somatic regulatory non-coding variants, we analyzed WGS and RNA-seq of this T-ALL to identify cis-activated genes that have

outlier expression using cis-X (version 1.4.0) a computational method for discovering regulatory noncoding variants in cancer by integrating whole-genome and transcriptome sequencing data from a single cancer sample(81). cis-X first finds aberrantly cis-activated genes that exhibit allele-specific expression accompanied by an elevated outlier expression. For each gene, outlier high expression of a cancer sample of interest was determined by comparing its expression level to those of reference samples with the same tissue type. A null distribution of 'leave-one-out (LOO)' t-statistic score was established using the reference samples. This was then used to determine the false discovery rate (FDR) of the LOO t-statistic score of a cancer sample of interest; those with an $FDR < 0.05$ were retained as having significant outlier high expression. A minimum of 20 cases is required for this analysis.

Data used for reference expression matrix were obtained from publicly available data on St. Jude Cloud or NCI TARGET to meet the minimum sample size criteria. For T-ALL samples such as SJTALL030071, RNA-seq data from 264 T-ALLs profiled by NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET)(41) was used as the reference expression matrix for evaluation of outlier expression status. For the remaining cancer subtypes that harbor candidate enhancer hijacking events (e.g., medulloblastoma (MB), B-lineage ALL (B-ALL) and acute myeloid leukemia (AML)), reference expression matrix were prepared by querying the relevant cancer diagnosis and selecting File Type "Feature Counts" (pre-calculated using Gencode V31) using the Data Browser of Genomic Platform of the St Jude Cloud(82). Feature counts were subsequently converted to reference FPKM matrix using DEseq2 for calculating outlier high expression status of samples presented in Supplemental Table S3. The AML reference expression matrix did not include therapy-related myeloid neoplasms. The number of samples used to construct the reference expression matrix for each cancer subtype is recorded in **Supplemental Table S3**.

For case SJTALL030071, we identified 18 genes that exhibit both allele-specific expression and outlier high expression surrounding *TLX3* (**Supplemental Table S17**). None of the genes other than *TLX3* play a known role in T-cell development or cancer. There were 29 consecutive SNPs with heterozygous genotypes in tumor DNA around the *TLX3* locus exhibiting mono-allelic expression in tumor RNA (see **Fig. 3C**).

Comparison to gene panels

We selected four commercially available gene panels: Foundation CDx, Foundation Heme, Thermo Fisher OncoPrint v3, and CHLA Oncokids in order to represent the breadth and diversity of clinical gene panels. Foundation CDx is a large general-use DNA-based panel, Foundation Heme is a large, combined DNA/RNA panel focused on hematological malignancies, Thermo Fisher OncoPrint v3 is a smaller DNA/RNA panel focused on adult cancers and Oncokids is a pediatric-specific version of the OncoPrint platform used in support of NCI's pediatric MATCH trial (see **Supplemental Tables 12** footnotes for further details).

All four panels are capable of detecting SNVs/indels, gene fusions and focal CNAs at the gene level. However, gross chromosomal changes cannot be officially reported by these assays. Additionally, complex copy number abnormalities such as chromothripsis and regions of loss of heterozygosity are not reported. Of 253 G4K patients, 75 patients (29.6%), predominantly with heme malignancies, had diagnostic, or prognostic gross chromosomal abnormalities including hyperdiploidy, hypodiploidy and iAMP21. However, an additional karyotype, FISH or microarray test could be run to detect these abnormalities. In order to make a direct comparison of reportable gene-level alterations we omitted gross chromosomal gains and losses from the analysis.

We arrived at a *conservative* estimate of how many reported and clinically actionable genes are not represented on the exemplar panels as follows:

1. We included both somatic and germline mutations in the comparison since our combined test reported both.
2. We used the coding sequence DNA portion of the panel assay for SNVs/indels/ITDs and focal CNAs. We assumed the observed alteration would have been captured and reported at the tumor VAF observed in the G4K patient. This is especially relevant for CNVs as panels generally only report homozygous deletions or multiple copy gains.
3. We used the RNA panel gene lists combined with intronic sequences designed to capture recurrent translocation breakpoints for fusions, enhancer hijacks and intragenic SVs.
4. We required only one of the partner genes to be present on the panel for gene fusions. This approach was permissive and enabled a conservative estimate of how many events might be detected by these technologies; we noted in our previous study that detection of gene fusions with low expression such as *KMT2A* rearrangement and *KIAA1549-BRAF* benefits from a multiplatform approach(14).
5. For enhancer hijacks, we were unable to determine if the translocation breakpoints that we observed by WGS were featured on current panel designs. Further, we did not assume outlier expression would be required on the panel data. As such we took the same approach as for gene fusions, requiring only one of the partner loci being present on the panel design.

If a G4K variant was covered by a given panel, it was tallied as detected (**Supplemental Table S12**). We evaluated all variants within each patient and if one variant was missed by a given panel, the patient was tallied as a miss by that panel (**Supplemental Table S13,14**).

Visualization of multi-omics data

To examine the impact of somatic variants within tumors, we used visual exploration of aggregated multi-omics data from PCGP, TARGET and other studies(15,20,41,42) using GenomePaint (<https://genomepaint.stjude.cloud/>).

Data availability

All raw and intermediate data are available as a free community resource hosted in St. Jude Cloud: <https://www.stjude.cloud> under accession number SJC-1004. Study level visualizations are available at <https://pecan.stjude.cloud>. Germline variants returned to patients during the study have been deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/submitters/506672/>).

Software/Code Availability

All software used in this study has been previously published; references are listed throughout the manuscript or are available in St. Jude Cloud. Further, our gene fusion, variant annotation and mutational signature pipelines are available on St. Jude Cloud (<https://www.stjude.cloud>).

ACKNOWLEDGEMENTS:

We thank the patients and families who participated in the G4K study, as well as each of the clinical and research staff who helped to make this study possible. We also gratefully acknowledge David Finkelstein for his assistance in preparing the final Figures.

This work was supported by funding provided by the American Lebanese Syrian Associated Charities and grants R01CA216354 (J Zhang, X Chen, X Zhou) and R01CA216391 (J Zhang, X Zhou) from the National Cancer Institute.

NOTE:

Chimene Kesserwan's present affiliation is with the National Institute of Health/National Cancer Institute, Center for Cancer Research, Cancer Genetics Branch. The opinions expressed in this article are the author's own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government.

REFERENCES

1. Chang W, Brohl AS, Patidar R, Sindiri S, Shern JF, Wei JS, *et al.* MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. *Clin Cancer Res* **2016**;22(15):3810-20 doi 10.1158/1078-0432.CCR-15-2717.
2. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, *et al.* Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. *Neuro Oncol* **2017**;19(5):699-709 doi 10.1093/neuonc/now254.
3. Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, *et al.* Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. *Genome Med* **2016**;8(1):133 doi 10.1186/s13073-016-0389-6.
4. Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, *et al.* Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. *JAMA Oncol* **2016**;2(5):616-24 doi 10.1001/jamaoncol.2015.5699.
5. Surrey LF, MacFarland SP, Chang F, Cao K, Rath KS, Akgumus GT, *et al.* Clinical utility of custom-designed NGS panel testing in pediatric tumors. *Genome Med* **2019**;11(1):32 doi 10.1186/s13073-019-0644-8.
6. Marks LJ, Oberg JA, Pendrick D, Sireci AN, Glasser C, Coval C, *et al.* Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. *Front Pediatr* **2017**;5:265 doi 10.3389/fped.2017.00265.
7. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. *Cancer Discov* **2017**;7(2):137-55 doi 10.1158/2159-8290.CD-16-1123.

8. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, *et al.* Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. *JAMA* **2015**;314(9):913-25 doi 10.1001/jama.2015.10080.
9. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, *et al.* Germline Mutations in Predisposition Genes in Pediatric Cancer. *N Engl J Med* **2015**;373(24):2336-46 doi 10.1056/NEJMoa1508054.
10. Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. *Semin Cancer Biol* **2020**;S1044-579X(20)30218-2 doi 10.1016/j.semcancer.2020.10.013.
11. Brok J, Lopez-Yurda M, Tinteren HV, Treger TD, Furtwangler R, Graf N, *et al.* Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms' tumour protocol database. *Lancet Oncol* **2018**;19(8):1072-81 doi 10.1016/S1470-2045(18)30293-6.
12. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, *et al.* Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. *J Clin Oncol* **1999**;17(11):3487-93 doi 10.1200/JCO.1999.17.11.3487.
13. Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, *et al.* Integrative clinical genomics of metastatic cancer. *Nature* **2017**;548(7667):297-303 doi 10.1038/nature23306.
14. Rusch M, Nakitandwe J, Shurtleff S, Newman S, Zhang Z, Edmonson MN, *et al.* Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. *Nat Commun* **2018**;9(1):3962 doi 10.1038/s41467-018-06485-7.

15. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, *et al.* Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* **2018**;555(7696):371-6 doi 10.1038/nature25795.
16. Howard Sharp KM, Jurbergs N, Ouma A, Harrison L, Gerhardt E, Taylor L, *et al.* Factors Associated with Declining to Participate in a Pediatric Oncology Next Generation Sequencing Study. *JCO Precis Oncol* **2020**;4:202-11 doi 10.1200/PO.19.00213.
17. Goschzik T, Gessi M, Dreschmann V, Gebhardt U, Wang L, Yamaguchi S, *et al.* Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. *J Neuropathol Exp Neurol* **2017**;76(2):126-34 doi 10.1093/jnen/nlw116.
18. Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, *et al.* The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature* **2018**;562(7727):373-9 doi 10.1038/s41586-018-0436-0.
19. Edmonson MN, Patel AN, Hedges DJ, Wang Z, Rampersaud E, Kesserwan CA, *et al.* Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. *Genome Res* **2019**;29(9):1555-65 doi 10.1101/gr.250357.119.
20. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, *et al.* The Pediatric Cancer Genome Project. *Nat Genet* **2012**;44(6):619-22 doi 10.1038/ng.2287.
21. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, *et al.* Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med* **2014**;371(11):1005-15 doi 10.1056/NEJMoa1403088.
22. Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, *et al.* Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. *Nat Med* **2020**;26(11):1742-53 doi 10.1038/s41591-020-1072-4.

23. He B, Gao P, Ding YY, Chen CH, Chen G, Chen C, *et al.* Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. *Sci Adv* **2020**;6(30):eaba3064 doi 10.1126/sciadv.aba3064.
24. Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, *et al.* Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. *Nature* **2014**;511(7510):428-34 doi 10.1038/nature13379.
25. Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, *et al.* MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. *Cancer Discov* **2018**;8(3):320-35 doi 10.1158/2159-8290.CD-17-0993.
26. Lehman NL, Usubalieva A, Lin T, Allen SJ, Tran QT, Mobley BC, *et al.* Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. *Acta Neuropathol Commun* **2019**;7(1):42 doi 10.1186/s40478-019-0689-3.
27. Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, *et al.* Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. *Genes Chromosomes Cancer* **2012**;51(12):1079-85 doi 10.1002/gcc.21992.
28. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, *et al.* Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. *Proc Natl Acad Sci U S A* **2008**;105(18):6708-13 doi 10.1073/pnas.0800408105.
29. Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, *et al.* The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. *PLoS Genet* **2012**;8(2):e1002533 doi 10.1371/journal.pgen.1002533.

30. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, *et al.* Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* **2009**;360(5):470-80 doi 10.1056/NEJMoa0808253.
31. Engelhardt KR, Xu Y, Grainger A, Germani Batacchi MG, Swan DJ, Willet JD, *et al.* Identification of Heterozygous Single- and Multi-exon Deletions in IL7R by Whole Exome Sequencing. *J Clin Immunol* **2017**;37(1):42-50 doi 10.1007/s10875-016-0343-9.
32. Marchuk DS, Crooks K, Strande N, Kaiser-Rogers K, Milko LV, Brandt A, *et al.* Increasing the diagnostic yield of exome sequencing by copy number variant analysis. *PLoS One* **2018**;13(12):e0209185 doi 10.1371/journal.pone.0209185.
33. Chen X, Gupta P, Wang J, Nakitandwe J, Roberts K, Dalton JD, *et al.* CONSERTING: integrating copy-number analysis with structural-variation detection. *Nat Methods* **2015**;12(6):527-30 doi 10.1038/nmeth.3394.
34. Phillips DH. Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair. *DNA Repair (Amst)* **2018**;71:6-11 doi 10.1016/j.dnarep.2018.08.003.
35. Van Hoeck A, Tjoonk NH, van Boxtel R, Cuppen E. Portrait of a cancer: mutational signature analyses for cancer diagnostics. *BMC Cancer* **2019**;19(1):457 doi 10.1186/s12885-019-5677-2.
36. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, *et al.* The repertoire of mutational signatures in human cancer. *Nature* **2020**;578(7793):94-101 doi 10.1038/s41586-020-1943-3.
37. Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, *et al.* Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. *Blood* **2020**;135(1):41-55 doi 10.1182/blood.2019002220.

38. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, *et al.* RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. *Nat Genet* **2014**;46(2):116-25 doi 10.1038/ng.2874.
39. Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M, Della Valle V, Monni R, *et al.* A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. *Leukemia* **2001**;15(10):1495-504 doi 10.1038/sj.leu.2402249.
40. Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, *et al.* A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat Med* **2014**;20(10):1130-7 doi 10.1038/nm.3665.
41. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, *et al.* The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat Genet* **2017**;49(8):1211-8 doi 10.1038/ng.3909.
42. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, *et al.* PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nat Genet* **2019**;51(2):296-307 doi 10.1038/s41588-018-0315-5.
43. Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, *et al.* Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. *Proc Natl Acad Sci U S A* **2017**;114(20):E4030-E9 doi 10.1073/pnas.1702489114.
44. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **2015**;17(5):405-24 doi 10.1038/gim.2015.30.

45. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, *et al.*
 Comprehensive Analysis of Hypermutation in Human Cancer. *Cell* **2017**;171(5):1042-56
 e10 doi 10.1016/j.cell.2017.09.048.
46. Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, *et al.*
 The landscape of genomic alterations across childhood cancers. *Nature*
2018;555(7696):321-7 doi 10.1038/nature25480.
47. Freitas AC, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, *et al.* Men seeking
 counselling in a Breast Cancer Risk Evaluation Clinic. *E cancer medical science*
2018;12:804 doi 10.3332/ecancer.2018.804.
48. Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, *et al.* Mutational
 processes shape the landscape of TP53 mutations in human cancer. *Nat Genet*
2018;50(10):1381-7 doi 10.1038/s41588-018-0204-y.
49. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, *et al.* Understanding the
 function-structure and function-mutation relationships of p53 tumor suppressor protein
 by high-resolution missense mutation analysis. *Proc Natl Acad Sci U S A*
2003;100(14):8424-9 doi 10.1073/pnas.1431692100.
50. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, *et al.*
 Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. *J Clin Oncol*
2015;33(21):2345-52 doi 10.1200/JCO.2014.59.5728.
51. Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F. Escape from
 p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-
 p53 axis. *Cell Death Differ* **2009**;16(12):1563-72 doi 10.1038/cdd.2009.138.
52. Agaimy A, Foulkes WD. Hereditary SWI/SNF complex deficiency syndromes. *Semin*
Diagn Pathol **2018**;35(3):193-8 doi 10.1053/j.semdp.2018.01.002.
53. Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, *et al.*
 Study of chromatin remodeling genes implicates SMARCA4 as a putative player in

- oncogenesis in neuroblastoma. *Int J Cancer* **2019**;145(10):2781-91 doi 10.1002/ijc.32361.
54. Wang Z, Wilson CL, Easton J, Thrasher A, Mulder H, Liu Q, *et al.* Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. *J Clin Oncol* **2018**;36(20):2078-87 doi 10.1200/JCO.2018.77.8589.
 55. Joseph L, Cankovic M, Caughron S, Chandra P, Emmadi R, Hagenkord J, *et al.* The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology. *J Mol Diagn* **2016**;18(5):605-19 doi 10.1016/j.jmoldx.2016.05.007.
 56. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, *et al.* Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn* **2017**;19(1):4-23 doi 10.1016/j.jmoldx.2016.10.002.
 57. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, *et al.* Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. *Cancer Discov* **2021**;11(6):1424-39 doi 10.1158/2159-8290.CD-20-0564.
 58. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, *et al.* Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *Eur J Cancer* **2016**;65:91-101 doi 10.1016/j.ejca.2016.06.009.
 59. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. *Blood* **2017**;130(19):2064-72 doi 10.1182/blood-2017-06-743252.
 60. Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, *et al.* Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. *J Natl Cancer Inst* **2017**;109(5) doi 10.1093/jnci/djw274.

61. Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, *et al.* Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. *Clin Cancer Res* **2017**;23(20):6101-12 doi 10.1158/1078-0432.CCR-17-0381.
62. Szabo Q, Bantignies F, Cavalli G. Principles of genome folding into topologically associating domains. *Sci Adv* **2019**;5(4):eaaw1668 doi 10.1126/sciadv.aaw1668.
63. Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukheim R, *et al.* Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. *Nat Genet* **2020**;52(3):294-305 doi 10.1038/s41588-019-0564-y.
64. Li L, Barth NKH, Pilarsky C, Taher L. Cancer Is Associated with Alterations in the Three-Dimensional Organization of the Genome. *Cancers (Basel)* **2019**;11(12) doi 10.3390/cancers11121886.
65. Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, *et al.* Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. *Cancer Res* **2017**;77(2):509-19 doi 10.1158/0008-5472.CAN-16-1106.
66. Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD. The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. *Pediatr Blood Cancer* **2017**;64(8) doi 10.1002/pbc.26441.
67. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group ACoMG, *et al.* A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med* **2015**;17(1):70-87 doi 10.1038/gim.2014.147.

68. Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, *et al.* Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *Am J Med Genet A* **2017**;173(4):1017-37 doi 10.1002/ajmg.a.38142.
69. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH. Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. *Bioinformatics* **2011**;27(6):865-6 doi 10.1093/bioinformatics/btr032.
70. Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, *et al.* CREST maps somatic structural variation in cancer genomes with base-pair resolution. *Nat Methods* **2011**;8(8):652-4 doi 10.1038/nmeth.1628.
71. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, *et al.* Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med* **2017**;19(2):249-55 doi 10.1038/gim.2016.190.
72. Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, *et al.* Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat* **2018**;39(11):1517-24 doi 10.1002/humu.23626.
73. Zhou X, Edmonson MN, Wilkinson MR, Patel A, Wu G, Liu Y, *et al.* Exploring genomic alteration in pediatric cancer using ProteinPaint. *Nat Genet* **2016**;48(1):4-6 doi 10.1038/ng.3466.
74. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, *et al.* COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res* **2011**;39(Database issue):D945-50 doi 10.1093/nar/gkq929.
75. Mikhail FM, Biegel JA, Cooley LD, Dubuc AM, Hirsch B, Horner VL, *et al.* Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint

- consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). *Genet Med* **2019**;21(9):1903-16 doi 10.1038/s41436-019-0545-7.
76. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **2009**;25(14):1754-60 doi 10.1093/bioinformatics/btp324.
 77. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **2013**;29(1):15-21 doi 10.1093/bioinformatics/bts635.
 78. Tian L, Li Y, Edmonson MN, Zhou X, Newman S, McLeod C, *et al.* CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. *Genome Biol* **2020**;21(1):126 doi 10.1186/s13059-020-02043-x.
 79. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics* **2015**;31(2):166-9 doi 10.1093/bioinformatics/btu638.
 80. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol* **2010**;11(10):R106 doi 10.1186/gb-2010-11-10-r106.
 81. Liu Y, Li C, Shen S, Chen X, Szlachta K, Edmonson MN, *et al.* Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X. *Nat Genet* **2020**;52(8):811-8 doi 10.1038/s41588-020-0659-5.
 82. McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, *et al.* St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. *Cancer Discov* **2021**;11(5):1082-99 doi 10.1158/2159-8290.CD-20-1230.

FIGURE LEGENDS

Figure 1. Patient accrual and demographic data. **A.** Consort diagram depicting patient accrual into G4K. Note: **(a)** Three patients were removed from the study when pathology revealed no cancer (1); the patient died before a germline sample could be collected (1); or the patient declined return of germline results and there was insufficient tumor for sequencing (1). **B.** Age distribution of patients. **C.** Number of patients with newly diagnosed, relapsed or refractory tumors, or no tumor available for sequencing, broken down by major tumor type. **D.** The distribution of cancer types represented in the G4K cohort (**top**) compared to the distribution of pediatric cancers in the NCI Surveillance, Epidemiology and End Results (SEER) program (**bottom**). **E.** Eighteen rare tumor types found in the G4K cohort present at less than 2 per million children annually in the United States

Figure 2. Somatic findings in the 253 analyzed tumors. **A.** Bar charts showing the numbers and relative contributions of mutational mechanisms affecting cancer genes in the tumors analyzed through G4K. The top 25 mutated genes for hematologic, CNS and solid tumors are shown as are gene fusions or enhancer hijack events for singletons in CNS and Solid Tumors. **B.** Gene fusions and enhancer hijacks detected in G4K samples. Number of samples with a given fusion are indicated in the left most column followed by the genes/loci involved and the diseases in which they were detected (see **Supplemental Fig. S3** for schematics depicting the 20 rare fusions). Black or red tiles indicate whether the identified gene fusions or enhancer hijacks have a clear or likely clinical utility, arranged into three columns indicating diagnostic (stethoscope), prognostic (patient chart), and therapeutically-relevant (target) categories. In the right most column (question mark), tiles indicate lesions with an unknown clinical utility, but considered biologically relevant to the tumor. Red disease names and tiles were identified in the rare tumors as shown in **Fig. 1E**. Disease abbreviations and additional details regarding SV classifications and literature citations can be found in **Supplemental Table 2**.

Figure 3. Using multi-omics data to interpret pathogenicity of structural variants. **A.**

GenomePaint plots showing two regions, chr8:128500000-130600000 (**top**) and chr5:170710000-170790000 (**bottom**) [hg19] from SJTALL030071. Both panels consist of the RefSeq gene model in green with *MYC* and *TLX3* highlighted by red boxes; orange bars show regions of copy number gain supported by increased whole genome sequencing coverage plotted as the blue histogram immediately below. Grey lollipops marked t(5;8) indicate the position of the translocation breakpoint. RNA-Seq coverage is shown below the whole genome coverage histogram. Additional data from TARGET is also shown with narrow red bars representing regions of copy number gain and grey lollipops representing structural variant breakpoints surrounding the *TLX3* locus. A region of recurrent copy number gain in TARGET samples is adjacent to the chromosome 8 breakpoint in SJTALL030071. Generally high but non-specific RNA-Seq coverage at this locus suggests a region of high transcriptional activity (distal *MYC* enhancer) is brought into proximity of *TLX3* by the translocation. **B.** A rank-order plot of TALL from TARGET showing expression levels of *TLX3* mRNA in a set of *TLX3*-activated tumors compared to tumors in which *TLX3* was not activated. SJTALL030071 *TLX3* expression (red dot) groups with the activated set. **C.** Allele-specific expression of the *TLX3* locus in SJTALL030071. The tumor DNA (top row) shows a series of heterozygous alleles in the *TLX3* locus (blue and red stacked bars show relative variant allele fraction from WGS data). In the RNA-Seq data (second row) expression of only one allele is observed. RNA coverage, read counts at each allele, are shown numerically (third row). Beneath the read counts, black lines map the locations of the alleles to the chromosome 5 coordinates surrounding *TLX3* locus. Beneath the coordinate line, the location of the SJTALL030071 translocation breakpoint is indicated. **D.** Two-dimensional t-SNE plot of RNA-Seq-derived gene expression data from 264 T-ALL samples(41). Major T-ALL subgroups are indicated on the plot with SJTALL030071 localizing among the *TLX3* cluster, as shown by the black arrow. **E.** Schematic representation of

an *ETV6-FOXO3* fusion found in SJBALL030052 joining the region N-terminal to the *ETV6* sterile alpha motif domain (green) with oligomerization interfaces (red) and ETS domain (purple), with the C-terminal *FOXO3* forkhead binding (green), KIX-binding (purple) and transactivation domains (red). **F.** Two-dimensional t-SNE plot of RNA-Seq-derived gene expression data from 1,988 B-ALL samples(42). Major subgroups are indicated on the plot with SJBALL030052 localizing to the periphery of the *ETV6-RUNX1* subgroup, as shown by the black arrow.

Figure 4. Germline variants and assessment of variant pathogenicity based on RNA data.

A. Numbers of germline P/LP variants, broken down by gene and tumor type. **B.** Proportions of germline P/LP variants, broken down by tumor type. **C.** *BAP1* intron 4 retention in SJEWS030332 compared to other G4K Ewing sarcoma cases. Each blue histogram shows hg19-aligned RNA-Seq coverage relative to the *BAP1* gene model in green (note that *BAP1* is on the negative strand). The position of the exon five splice acceptor mutation is indicated by the red dotted line. Increased read coverage in the SJEWS030332 (bearing a mutation at the -3 position of exon 5) intron relative to the three other samples indicates intron 4 retention (black arrow). Inset histograms show the relative proportion of reference and variant alleles in tumor-derived WGS and RNA-Seq in grey and purple, respectively. Corresponding read counts are WGS: 32G/21T (40% variant allele) and RNA 2G/28T (93% variant allele). Above the RNA coverage plots a schematic of the *BAP1* protein is shown with the location of the splice variant leading to protein truncation marked. **D.** *NF1* exon 45 skipping in SJBALL030144. The blue histogram shows RNA-Seq coverage relative to the *NF1* gene model in green. Canonical splices are shown as light blue links between exons and a non-canonical splice is shown in mauve. The height of mauve and blue lollipops is proportional to the number of splice junction reads detected plotted on a log scale on the y-axis. The purple bar indicates the position of the *NF1* exon 45 splice acceptor mutation. Exon 45 expression is diminished relative to flanking

exons and a non-canonical splice linking exons 44 and 46 is observed indicating an exon skipping event.

Figure 5. The impact of somatic variation in establishing disease relevance of deleterious germline variants. Each row represents a unique patient. From left to right the columns are as follows: ‘Case ID’, the last 4 digits of the patients’ IDs (compare **Supplemental Table 8, Column A**). ‘Diagnosis,’ gives the disease code used internally (compare **Supplemental Table S8, Column B**). Note, matched superscripts indicate mutations in the same patient. ‘Germline Variant’ lists the gene and amino acid change. Germline Testing Indicated, signifies patients whose cancer or other phenotypic characteristics suggested the patient and possibly the family should undergo germline testing (black tiles). ‘Germline Genotype,’ gives the genotype of the variant indicated in the Germline Variant column. ‘Second Hit Category’ gives the genetic configuration of any genetic or epigenetic alterations affecting the remaining wildtype gene copy in the tumor. ‘Molecular Phenotype’ pertains to evidence in the DNA sequence of the tumor as to the activity of the germline variant. Molecular phenotypes included features such as splice aberrations visible in the RNA-Seq data and mutation signatures. Tumor second hits and molecular phenotype were not available for some patients due to absence or inadequate tumor for testing (see Methods). The 5 columns of tiled cells are sorted to group germline mutations by ‘Disease Related’ and then secondarily by ‘Germline Testing Indicated’.

Figure 6. Evaluation of germline and tumor data to establish disease relevance. A. P53 A161T is a weakly functional likely pathogenic p53 variant in SJNBL030203. Six markers, including the germline variant C>T at chr17:7578449 (demarked by upside down triangle) are represented by 3 rows of vertical bars. The bars are colored red and blue to show the allele fractions in WGS data. The rows indicating germline and tumor DNA show most positions as heterozygous with both red and blue portions. In the RNA, all markers are mono-colored


indicating that only one allele is expressed. At the location of the germline variant (C>T), the bar is completely red, indicating that only the variant allele is expressed, suggesting that the wild-type allele is transcriptionally silenced. **B.** A pathogenic *MUTYH* germline founder mutation, G396D, in RB patient SHRB030050. **C.** The tumor mutation burden (TMB) for SHRB030050, from WGS data, is in upper quartile compared to other RB patients including those from St Jude Cloud. Box includes the 2nd to 3rd quartiles; horizontal bar within box is median. **D.** Mutation signatures from WGS data from RB patients available in G4K and from the Pediatric Cancer Genome Project in the St Jude Cloud resource (<https://www.stjude.cloud/>). Sixty percent of tumor mutations in SHRB030050 are attributable to damage by reactive oxygen species (ROS). **E.** TMB plots of brain and hematologic tumors. The three tumors that are hypermutated (those with >10 mutations/Mb) are labeled with patient ID and the genes that were mutated to cause hypermutation. A fourth brain tumor with a TMB close to median was heterozygous for mutation of *PMS2*. The two hypermutated patients with *PMS2* carried compound heterozygous mutation of the gene. The patient with the highest TMB also carried a S459F mutation of *POLE*. **F.** Mutation signatures of the patients in panel (E). **G.** Immunohistochemical staining for the indicated mismatch repair proteins in the brain tumors of patients SJHGG030336 and SJBT030067. **Top.** Infiltrative astrocytoma with severe cytologic atypia, mitotic activity, and necrosis; diagnostic of glioblastoma. Immunohistochemistry for mismatch repair proteins exhibited loss of *MSH2* and *MSH6*, but retained staining in stromal elements. **Bottom.** Gastrointestinal-type adenocarcinoma arising in malignant mixed germ cell tumor. Staining for mismatch repair proteins demonstrated retained expression of *MSH2*, *MSH6*, *PMS2*, and *MLH1*. All images are 40X magnification; scale bars represent 40 microns.

Figure 7. Clinically actionable findings. **A.** Tile plot summarizing clinically actionable findings in the 253 patients who had both tumor and normal tissues sequenced. Each tumor is represented as a row and is grouped according to major tumor type. Columns represent the


presence (blue) or absence (white) of a diagnostic (stethoscope), prognostic (patient chart), therapeutically-relevant (target) or cancer predisposing mutation (pedigree). **B.** Tumors with targetable (Tier 1 and 2, green) or potentially targetable (blue) lesions, categorized by the affected gene, identified by the three-platform sequencing approach. Additional information can be found in **Supplemental Tables S2, S10.** **C.** Swimmer plot depicting patients receiving a targeted therapy matched to their tumor genetic lesion. Each bar is one patient, with the disease as labeled. Pink bars, patient is alive; blue bars, patient is deceased. Best response on the targeted therapy is as labeled. CR, complete response; PR, partial response; SD stable disease; PD, progressive disease. The drugs used are labeled adjacent to each bar. See **Supplemental Table S11** for further details. MPAL, mixed phenotype acute leukemia; B-ALL, B-acute lymphoblastic leukemia; T-ALL, T acute lymphoblastic leukemia; AML, acute myeloid leukemia.

Figure 1.


A.




B.




C.




D.



E.




A.




B.

#	Gene A	Gene B	Disease	U	W	G	?
19	ETV6	RUNX1	B-ALL				
18	KMT2A	various	B-ALL				
7	KIAA1549	BRAF	LGG				
4	EWSR1	FLI1	EWS				
4	RUNX1	RUNX1T1	AML				
4	PAX5	various	B-ALL				
3	P2RY8	CRLF2	B-ALL				
2	BCR	ABL1	B-ALL				
2	C11orf95	RELA	EPD				
2	CBFB	MYH11	AML				
2	PML	RARA	AML				
1	PAX3	FOXO1	RHB				
1	STIL	TAL1	T-ALL				
1	STRN	ALK	THY				
4	enhancer	TLX3	T-ALL				
4	enhancer	CRLF2	B-ALL				
4	enhancer	DUX4	B-ALL				
3	enhancer	LMO2	T-ALL				
2	enhancer	MECOM	AML				
1	enhancer	NKX2-1	T-ALL				
1	enhancer	GFI1B	MB				
1	enhancer	CEBPD	B-ALL				
1	enhancer	TERT	MEL				
1	enhancer	EPOR	B-ALL				
1	CBFA2T3	GLIS2	AML				
1	CIC	NUTM1	PNET				
1	CLIP2	ALK	HGG				
1	COL1A1	USP6	DES				
1	EPS15L1	KLF17	CCM				
1	ETV6	FOXO3	B-ALL				
1	EWSR1	WT1	DSCRT				
1	GATA3	TERT	NBL				
1	GOPC	ROS1	T-ALL				
1	KDM2B	PARK2	MGCT				
1	MAP3K8	GNG2	MEL				
1	MEF2D	BCL9	B-ALL				
1	MN1	CXXC5	HGNET				
1	MOB2	TERT	DSCRT				
1	NR1D1	MAML1	PDC				
1	PRKAR2B	MET	PRCC				
1	RBM15	MKL1	AML				
1	TCF7	SPI1	T-ALL				
1	TUB	FSTL5	MB				
1	YAP1	MAMLD1	EPD				


A.




B.




C.



D.



E.



F.






Figure 4.


A.



B.



C.



D.

SJBALL030144




Figure 5.




Figure 6.





Figure 7.



CANCER DISCOVERY

Genomes for Kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing

Scott Newman, Joy Nakitandwe, Chimene A Kesserwan, et al.

Cancer Discov Published OnlineFirst July 23, 2021.

Updated version	Access the most recent version of this article at: doi: 10.1158/2159-8290.CD-20-1631
Supplementary Material	Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2021/07/21/2159-8290.CD-20-1631.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/early/2021/07/21/2159-8290.CD-20-1631 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.